The U.S. and several European countries object to an intellectual property rights bill likely to be approved by the Israeli government. The measure would only provide marketing exclusivity for pharmaceutical firms, but not protect confidentiality of proprietary tests and clinical data used to register a drug, thus allowing Israeli generic firms to produce drug copies. The issue prompted representatives of Germany, France, Denmark and Switzerland to express concern over Israel's unwillingness to honor European trade agreements.

Related Summaries